SCHEMBL6484427

SCHEMBL6484427

COc1ccccc1CNc1cccc2c1oc1ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.57
L3MBTL1 Q9Y468 2/20 0.55
ACHE P22303 1/20 0.54
GAA P10253 3/20 0.51
ALDH1A1 P00352 7/20 0.49
KDM4E B2RXH2 6/20 0.49
MAPT P10636 6/20 0.49
HPGD P15428 5/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
GPR55 Q9Y2T6 1/20 0.49
RAB9A P51151 2/20 0.48
LMNA P02545 2/20 0.48
NPC1 O15118 1/20 0.48
MAOA P21397 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481798 0.91 HDAC8 (0.57) HDAC8L3MBTL1ACHEGAAALDH1A1
SCHEMBL6494857 0.87 HDAC8 (0.47) HDAC8L3MBTL1ACHEGAAALDH1A1
SCHEMBL6483561 0.87 HDAC8 (0.55) HDAC8L3MBTL1ACHEGAAALDH1A1
SCHEMBL6484144 0.82 HDAC8 (0.47) HDAC8L3MBTL1ACHEGAAALDH1A1
SCHEMBL6483874 0.81 HPGD (0.63) HDAC8L3MBTL1ACHEGAAALDH1A1
SCHEMBL6482988 0.80 CA12 (0.58) HDAC8L3MBTL1GAAALDH1A1KDM4E
SCHEMBL6494308 0.79 EGFR (0.59) HDAC8L3MBTL1ALDH1A1KDM4EMAPT
SCHEMBL6482996 0.78 MAPT (0.49) HDAC8L3MBTL1ACHEGAAALDH1A1
SCHEMBL6495698 0.78 ABCB1 (0.52) HDAC8L3MBTL1ACHEGAAALDH1A1
SCHEMBL6485764 0.78 RXFP1 (0.44) HDAC8L3MBTL1ACHEGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 HDAC8 1/4885L3MBTL1 3832/4885ACHE 1631/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 HDAC8 1/4885L3MBTL1 2831/4885ACHE 3316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.